

Gefitinib IPASS

PRELIMINARY SCORE

CURATIVE



NON-CURATIVE




ADJUSTMENTS

Quality of life



Improved QoL

Serious and disabling adverse effects



Less serious and disabling adverse events observed


Other adjustments



Gefitinib IPASS

FINAL SCORE

CURATIVE



Overall Survival / Disease-Free Survival / Pathological Complete Response

NON-CURATIVE



Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Tumour type: Thoracic Malignancies
Therapeutic Indication: Treatment of adult patients with locally advanced or metastatic NSCLC with activating mutations of EGFR tyrosine kinase.
Experimental Arm: Gefitinib
Control Arm: Carboplatin + paclitaxel



